27611-63-8

Usage

Uses

Used in Organic Synthesis:
2-Cyanobenzoyl Chloride is used as an acyl donor for [application reason] in the synthesis of various organic compounds. Its reactivity and ability to form new chemical bonds make it a valuable component in the development of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2-Cyanobenzoyl Chloride is used as a derivatizing agent for [application reason], enabling the modification of existing compounds to enhance their properties or create new drugs with improved therapeutic effects.
Used in Agrochemical Industry:
2-Cyanobenzoyl Chloride is utilized as a key intermediate in the synthesis of agrochemicals, serving as a building block for the development of new pesticides or herbicides with increased efficacy and selectivity.
Used in Specialty Chemicals:
2-Cyanobenzoyl Chloride is employed as a versatile reagent in the production of specialty chemicals, such as dyes, fragrances, and polymers, where its unique properties contribute to the desired characteristics of the final products.

InChI:InChI=1/C8H4ClNO/c9-8(11)7-4-2-1-3-6(7)5-10/h1-4H

Upstream product

• 3839-22-3 2-cyanobenzoic acid 
• 6587-24-2 methyl 2-cyanobenzoate 
• 88-97-1 phthalamic acid 
• 10026-13-8 phosphorus pentachloride 
• 136918-14-4 phthalimide 

Downstream Products

• 22517-57-3 2-<(2-Methylhydrazino)-methyl>-benzamid 
• 26487-08-1 2-cyano-N,N-dimethylbenzamide 
• 26487-09-2 2-cyano-N,N-diethylbenzamide 
• 34446-13-4 2-cyano-N-phenylbenzamide 
• 134425-25-5 3-n-butyl-5-<(4-chlorobenzyl)thio>-4-<4-<(2-cyanobenzyl)amino>benzyl>-4H-1,2,4-triazole 
• 1027168-61-1 N-{4-[3-Butyl-5-(4-methoxy-benzylsulfanyl)-[1,2,4]triazol-4-ylmethyl]-phenyl}-2-cyano-benzamide 
• 253668-47-2 2-(1H-benzo[d][1,2,3]triazole-1-carbonyl)benzonitrile 
• 159589-69-2 4'-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]-2-cyanobenzanilide 
• 76889-76-4 2-(1H-benzo[d]imidazol-2-yl)benzonitrile 
• 145303-61-3 3-[N-(2-cyanobenzoyl)-5-indolyl]methyl-5,7-dimethyl-2-ethyl-3H-imidazo[4,5-b]pyridine 
• 1201922-36-2 2-(2-cyanophenyl)-5-(p-tolylamino)-4-(p-tolylimino)-4H-imidazole 
• 840490-44-0 6-[4-(2-cyanobenzoyl)piperazin-1-yl]-pyridazine-3-carboxylic acid (2-cyclopropylethyl)amide 
• 19731-00-1 o-Cyan-benzoesaeure-hydrazid 

Relevant academic research and scientific papers

Lead derivatization of ethyl 6-bromo-2-((dimethylamino)methyl)-5-hydroxy-1-phenyl-1H-indole-3-carboxylate and 5-bromo-2-(thiophene-2-carboxamido) benzoic acid as FabG inhibitors targeting ESKAPE pathogens

Our previous studies on FabG have identified two compounds 5-bromo-2-(thiophene-2-carboxamido) benzoic acid (A) and ethyl 6-bromo-2-((dimethylamino)methyl)-5-hydroxy-1-phenyl-1H-indole-3-carboxylate(B) as best hits with allosteric mode of inhibition. FabG is an integral part of bacterial fatty acid biosynthetic system FAS II shown to be an essential gene in most ESKAPE Pathogens. The current work is focussed on lead expansion of these two hit molecules which ended up with forty-three analogues (twenty-nine analogues from lead compound A and fourteen compounds from lead compound B). The enzyme inhibition studies revealed that compound 15 (effective against EcFabG, AbFabG, StFabG, MtFabG1) and 19 (inhibiting EcFabG and StFabG) had potency of broad-spectrum inhibition on FabG panel.

Combined Cyanoborylation, C-H Activation Strategy for Styrene Functionalization

A one-pot multicomponent copper-catalyzed protocol for borylation/ortho-cyanation of styrene derivatives followed by a Suzuki-Miyaura coupling provides a platform to explore the factors that control the selectivity between distal or proximal functionalization of arenes. The development of divergent nitrile-directed C-H functionalization (acetoxylation, pivalation, and methoxylation) offers an effective approach to rapidly increase synthetic complexity. Finally, the development of a mild reductive decyanation allows a traceless method to access functionalized biaryl motifs.

Nitrogenous heterocyclic compound with nematocidal activity, preparation method and application thereof

The invention relates to a nitrogenous heterocyclic compound with nematocidal activity, a preparation method and application thereof. Specifically, the invention discloses a compound with a formula (I) or an optical isomer, cis-trans isomer or acceptable salt in agricultural pharmacology and a preparation method thereof. The invention further discloses an agricultural composition containing the compound and application thereof. The compound has excellent nematocidal activity.

Ortho lithiation-in situ borylation of substituted morpholine benzamides

Morpholine amides are cheap and safe alternative to Weinreb amides as acylating agents of organometallic species. Herein, the in-situ lithiation/borylation of 18 ortho- meta- and para-substituted morpholine benzamides has been investigated. 10 of the 18 substrates provided the desired boronic esters as the major isomer (>90% regioselectivity) in crude isolated yields ranging from 68 to 93%. The synthetic usability of such building blocks was subsequently illustrated via the synthesis of a kinase inhibitor.

Mapping the structural boundaries of quasiracemate fractional crystallization using 2-substituted diarylamides

Video-assisted hot stage polarized light microscopy of 55 quasienantiomeric pairs, constructed from 22 chiral diarylamides that systematically differ in topology, reveals the structural boundaries of molecular shape to supramolecular assembly.

Synthesis and evaluation of novel azoles as potent antifungal agents

Using a rational approach to the design of antifungal agents, a series of azole agents with 1,3,4-oxadiazole side chains were designed and synthesized. The results of preliminary in vitro antifungal tests with eight human pathogenic compounds showed that all of the title compounds exhibited excellent activities against all of the tested fungi except Aspergillus fumigatus. Compounds 11e and 11f were found to be the most effective, with a minimum inhibitory concentration of 0.0039 μg/mL, followed by voriconazole, which has a MIC of 0.0625 μg/mL. The 1,3,4-oxadiazole side chain is not the major contributor but plays a role in eliciting the observed antifungal activity.

The synthesis of carboxy- and cyano-substituted 4H-imidazoles: Redoxactive ligands as starting materials for metal-metal multiply bonded compoundsand heterobimetallic complexes

Cyanobenzoic acids proved to be suitable starting materials for the transformation into multifunctional products of the 4H-imidazole type. Employing two different pathways, the new derivatives 1b-d which possess carboxy/cyano groups were synthesized. In addition, derivative 1d formed the basis for the construction of novel bis-4H-imidazoles with two different complexation spheres. The structures of all new derivatives were confirmed by NMR spectroscopy, mass spectrometry, elemental analysis, UV/Vis-/fluorescence spectroscopy, and electrochemical measurements.

Benzimidazol-2-yl or benzimidazol-2-ylthiomethyl benzoylguanidines as novel Na+/H+ exchanger inhibitors, synthesis and protection against ischemic-reperfusion injury

A novel series of benzimidazol-2-yl or benzimidazol-2-ylthiomethyl benzoylguanidines were designed and synthesized as Na+/H+exchanger inhibitors. Most of them were found to inhibit NHE1-mediated platelet swelling in a concentration-dependent manner, and to have significant cardioprotective effect against myocardial ischemic-reperfusion injury, among which compounds 10a and 34 were more potent than cariporide in both in vivo and in vitro tests.

Preparation of highly potent and selective non-peptide antagonists of the arginine vasopressin V1A receptor by introduction of a 2-ethyl-1H-1-imidazolyl group

To find a new series of arginine vasopressin (AVP) V1A receptor antagonists, the influence of the 2-phenyl group of 2-phenyl-4′-[(2,3,4,5- tetrahydro-1H-1-benzazepin-1-yl)carbonyl]benzanilide (7) was investigated. Replacement of the 2-phenyl group by a 2-ethyl-1H-imidazol-1-yl group was effective in yielding a V1A-selective compound. Moreover, this imidazolyl group was introduced in the same position in YM-35471 (6), and further studies of these compounds were performed. Consequently, we found that the (Z)-4′-({4,4-difluoro-5-[(N-cyclo-propylcarbamoyl) methylene]-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl}carbonyl)-2-(2-ethyl-1H-1- imidazol-1-yl)benzanilide (9f) exhibited highly potent affinity and selectivity, and was the most potent antagonist for the V1A receptor among our compounds. The synthesis and pharmacological evaluation of these compounds are described in this paper

CCR8 INHIBITORS

Disclosed is an inhibitor of CCR8 that is represented by Structural Formula (I). Also disclosed are pharmaceutical compositions comprising a pharmaceutically acceptable carrier or diluent and a CCR8 inhibitor represented by Structural Formula (I). Also disclosed is a method of treating inflammatory disorders in a subject by administering a CCR8 inhibitor to the subject.